Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
Friday, AbbVie Inc (NYSE:ABBV) reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23.
周五，艾伯维公司（纽约证券交易所代码：ABBV）公布的第一季度调整后每股收益为2.31美元，同比下降6.1％，超过市场预期的2.23美元。
Net revenues reached $12.31 billion, up 0.7%, beating the consensus of $11.92 billion. Sales were up 1.6% on an operational basis.
净收入达到123.1亿美元，增长0.7％，超过了市场普遍预期的119.2亿美元。销售额在运营基础上增长了1.6％。
"First quarter results were well ahead of our expectations, driven by excellent performance from our ex-Humira growth platform," said Robert Michael, president and chief operating officer.
总裁兼首席运营官罗伯特·迈克尔表示：“在我们前Humira增长平台的出色表现的推动下，第一季度的业绩远超出了我们的预期。”
The immunology portfolio generated $5.37 billion in sales, down 3.9% on a reported basis or 3.1% on an operational basis, due to Humira biosimilar competition.
由于Humira生物仿制药的竞争，免疫学产品组合创造了53.7亿美元的销售额，按报告计算下降了3.9％，运营方面下降了3.1％。
Humira revenues were $2.27 billion (down 35.9%), Skyrizi sales reached $2.01 billion (up 47.6%), and Rinvoq revenues were $1.09 billion (up 59.3%).
Humira的收入为22.7亿美元（下降35.9％），Skyrizi的销售额达到20.1亿美元（增长47.6％），Rinvoq的收入为10.9亿美元（增长59.3％）。
Related: AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study.
相关： 在正面交锋的研究中，艾伯维的皮炎药物显示出 “优于” 赛诺菲/Regeneron的Dupixent。
Last month, AbbVie agreed to acquire Landos Biopharma Inc (NASDAQ:LABP) for $20.42 per share, or approximately $137.5 million, plus one contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million.
上个月，艾伯维同意以每股20.42美元，合约1.375亿美元的价格收购兰多斯生物制药公司（纳斯达克股票代码：LABP），外加每股一项或有价值的权利，价值最高为11.14美元，约合7,500万美元。
Oncology product sales were $1.54 billion, up 9% or 9.8% on an operational basis.
肿瘤产品销售额为15.4亿美元，按运营水平增长9％，增长9.8％。
Imbruvica revenues were $838 million (down 4.5%), Venclexta sales increased 14.2% to $614 million, and Elahere net revenues were $64 million, reflecting a partial quarter of sales based on February 12, 2024, close date of the ImmunoGen acquisition.
Imbruvica的收入为8.38亿美元（下降4.5％），Venclexta的销售额增长了14.2％，至6.14亿美元，Elahere的净收入为6400万美元，反映了基于2024年2月12日，即ImmunoGen收购截止日期的部分销售额。
Neuroscience revenues reached $1.97 billion, up 15.9% on a reported basis or 16% on an operational basis.
神经科学收入达到19.7亿美元，按报告计算增长15.9％，运营收入增长16％。
Botox Therapeutic sales were $748 million, up 4.1%. Aesthetics portfolio sales reached $1.25 billion, down 4%. Global Botox Cosmetic revenues were $633 million, down 3.9%.
肉毒杆菌毒素治疗的销售额为7.48亿美元，增长4.1％。美学投资组合销售额达到12.5亿美元，下降4％。全球肉毒杆菌毒素化妆品收入为6.33亿美元，下降3.9％。
Guidance: AbbVie raised its 2024 adjusted EPS guidance from $10.97-$11.17 to $11.13-$11.33, which includes an unfavorable impact of $0.08 per share related to acquired IPR&D and milestones expense incurred during the first quarter of 2024, versus consensus of $11.12.
指导方针：艾伯维将其2024年调整后的每股收益预期从10.97美元上调至11.13美元至11.33美元，其中包括与收购的知识产权研发相关的每股0.08美元的不利影响，以及2024年第一季度产生的里程碑支出，而市场预期为11.12美元。
Price Action: ABBV shares are down 3.41% at $161.58 at the last check Friday.
价格走势：周五最后一次支票时，ABBV股价下跌3.41％，至161.58美元。
Photo via Company
照片来自公司